Trastuzumab resistance accompanies vasculogenic mimicry in HER2-positive breast cancer cells

被引：0
|
作者：
Shimoda, Masafumi [1 ]
Noguchi, Shinzaburo [1 ]
机构：
[1] Osaka Univ, Sch Med, Dept Breast Endocrine Surg, Suita, Osaka, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
J-1031
引用
收藏
页码：311 / 311
页数：1
相关论文
共 50 条
  • [31] Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy
    Derakhshani, Afshin
    Rezaei, Zohreh
    Safarpour, Hossein
    Sabri, Morteza
    Mir, Atefeh
    Sanati, Mohammad Amin
    Vahidian, Fatemeh
    Moghadam, Ali Gholamiyan
    Aghadoukht, Ali
    Hajiasgharzadeh, Khalil
    Baradaran, Behzad
    JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (04) : 3142 - 3156
  • [32] HER3 activation by MET contributes to trastuzumab resistance in HER2-positive breast cancer
    Hashimoto, Kenji
    Macaulay, Valentine
    Kong, Anthony
    CANCER RESEARCH, 2014, 74 (19)
  • [33] Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells
    Chi Zhang
    Xuening Duan
    Ling Xu
    Jingming Ye
    Jianxin Zhao
    Yinhua Liu
    Breast Cancer Research and Treatment, 2012, 136 : 739 - 748
  • [34] Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells
    Zhang, Chi
    Duan, Xuening
    Xu, Ling
    Ye, Jingming
    Zhao, Jianxin
    Liu, Yinhua
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (03) : 739 - 748
  • [35] Predictive factors of resistance to trastuzumab as neoadjuvant therapy in women with HER2-positive breast cancer
    Jinno, Hiromitsu
    Sato, Tomomi
    Takahashi, Maiko
    Hayashida, Tetsu
    Hirose, Shigemichi
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [36] Albumin-bilirubin score predicts trastuzumab resistance in HER2-positive breast cancer
    Huang, Wen-Juan
    Yuan, Jia-Rui
    Zhang, Lei
    Wang, Wen
    Miao, Shi-Di
    Wang, Xin
    Wang, Rui-Tao
    CANCER BIOMARKERS, 2023, 38 (04) : 425 - 432
  • [37] Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents
    Wang, Zhen-hao
    Zheng, Zhuo-qun
    Jia, Shi-cheng
    Liu, Shu-ni
    Xiao, Xiao-fen
    Chen, Guan-yuan
    Liang, Wei-quan
    Lu, Xiao-feng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [38] CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
    Xing, Fei
    Gao, Hongli
    Chen, Guanglei
    Sun, Lisha
    Sun, Jiayi
    Qiao, Xinbo
    Xue, Jinqi
    Liu, Caigang
    MOLECULAR CANCER, 2023, 22 (01)
  • [39] Mechanisms behind trastuzumab resistance as neoadjuvant therapy in HER2-positive operable breast cancer
    Jinno, H.
    Sato, T.
    Hayashida, T.
    Takahashi, M.
    Hirose, S.
    Kitagawa, Y.
    CANCER RESEARCH, 2012, 72
  • [40] Association of Rac1 Expression with Trastuzumab Resistance In HER2-Positive Breast Cancer
    Varol, Umut
    Karaca, Burcak
    Patir, Pusem
    Sener, Alper
    Zekioglu, Osman
    Sanli, Ulus A.
    Uslu, Ruchan
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2013, 23 (04): : 219 - 226
12345